© Springer Nature Switzerland AG 2021
C. S. Foster et al. (eds.)Uveitishttps://doi.org/10.1007/978-3-030-52974-1_28

28. Bartonella

Artur Filipowicz1  
(1)
Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA
 
Keywords
BartonellaUveitis

Overview

  • Definition
    • Gram-negative , oxidase-negative aerobic bacilli that reside in human RBCs and endothelial cells
      • Multiple species exist, 8 of 21 are pathologic to humans

    • Bartonella henselae commonly associated with neuroretinitis, cat-scratch disease (CSD), Parinaud’s oculoglandular syndrome (POGS)

  • Symptoms
    • Decreased vision, 20/25 to 20/200, may be worse

    • Floaters

    • Redness

    • Irritation

  • Laterality
    • Mostly unilateral, can be bilateral and asymmetric

  • Course
    • Onset of ocular symptoms 1 month after inoculation

    • Typically improves in 2–3 months with treatment

  • Age of onset
    • Any age, more common in children and adolescents

  • Gender/race
    • Occurs worldwide

  • Systemic association
    • Cat-scratch disease

    • Parinaud’s oculoglandular syndrome

Exam: Ocular

Anterior Segment

  • Follicular conjunctivitis
    • Conjunctival granuloma if primary site of inoculation

  • Anterior uveitis

  • +/− APD

Posterior Segment

  • Vitritis

  • Neuroretinitis
    • Optic disc edema, significant

    • Macular star – radial lipid exudates, may be outside macula

    • May resolve in 8–12 weeks

  • Focal or multifocal retinitis or choroiditis, mass
    • May be highly vascular and resemble bacillary angiomatosis

  • Retinal vasculitis
    • Intraretinal hemorrhages and retinal ischemia

    • Vascular occlusion (BRAO or BRVO)

  • Serous macular detachment

Exam: Systemic

  • Transmission through cat scratch or bite or open wounds exposed to cat saliva or flea feces

  • Systemic findings after inoculation
    • 3–10 days – focal granuloma, small erythematous papule on skin at site of bite/scratch

    • 7–14 days – conjunctival injection, chemosis, and water discharge

    • 2–3 weeks – regional lymphadenopathy, malaise, myalgias, fatigue, low-grade fever (faded skin papule)

  • Immunocompromised patients
    • May develop disseminated disease – endocarditis, meningitis, arthritis, osteomyelitis, pneumonia, hepatosplenomegaly

Imaging

  • OCT: macular thickening, intraretinal hyperreflective deposits, subretinal fluid, disc thickening

  • OCT-A: telangiectasias near disc

  • FA: early peripapillary telangiectasias with disc and vascular leakage; late disc leakage

  • Perimetry: cecocentral scotoma, paracentral scotoma, enlarged blind spot

  • VEP: reduced amplitude and increased latency in affected eye

Laboratory and Radiographic Testing

  • Serologic testing, IgG, IgM
    • Indirect fluorescent antibody (IFA)
      • 88% sensitivity and 94% specificity

    • Enzyme immunoassay (EIA) and Western blot
      • 86–95% sensitivity and 96% specificity for IgG

      • Potential for cross-reactivity between species

    • PCR

Differential Diagnosis

  • Toxocariasis

  • Tuberculosis

  • Syphilis

  • Lyme disease

  • Sarcoidosis

  • Behcet disease

  • Rickettsiosis

  • Chikungunya

  • Systemic hypertension

  • Diabetic papillopathy

  • Anterior ION

  • Papilledema

Treatment

  • No consensus on treatment

  • May be observed in mild-to-moderate immunocompetent patient

  • Doxycycline 100 mg BID PO × 10–14 days in >8 years old
    • May also give erythromycin, TMP-SMX, rifampin, or IM gentamycin

  • Severe infection – IV doxycycline and erythromycin with rifampin

  • Prednisone with antibiotics, 1 mg/kg/day with taper

  • Immunocompromised patients may require treatment up to 4 months

  • Conjunctival infections may be treated with combination drops and oral

Referral/Comanagement

  • Infectious disease specialist

  • Other consults depending on presenting systemic symptoms